Tag: US viral inactivation market

  • Viral Inactivation Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Viral Inactivation Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Viral Inactivation Market Value Expansion And Long-Term Growth Outlook

    The market dedicated to viral inactivation has experienced substantial expansion recently. Projections indicate a rise from $5.47 billion in 2025 to $6.05 billion in 2026, demonstrating a compound annual growth rate of 10.6%. Key drivers behind this historical growth trajectory include a surge in the production of plasma-derived therapeutics, an increase in the manufacturing capabilities for monoclonal antibodies, heightened scrutiny from regulatory bodies concerning viral safety protocols, the broadening of biopharmaceutical production infrastructure, and a greater prevalence in the utilization of solvent detergent techniques.

    The viral inactivation sector is poised for substantial expansion over the coming years, with projections indicating it will reach a value of $9.17 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.9%. This projected surge is fueled by several key factors, including a heightened need for biologics and biosimilars, increased funding directed towards sophisticated bioprocessing infrastructure, a greater emphasis on continuous manufacturing practices, wider implementation of automated quality assurance mechanisms, and the broadening scope of vaccine development pipelines. During this forecast period, prominent trends are expected to include a more widespread embrace of automated viral inactivation technologies, a growing emphasis on rigorously validated virus safety protocols, the increasing utilization of continuous flow inactivation techniques, the further proliferation of single-use bioprocessing solutions, and a stronger commitment to ensuring process consistency and regulatory adherence.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    Viral Inactivation Market Growth Factors: Which Forces Are Supporting Market Expansion?

    The increasing prevalence of diverse infectious diseases is anticipated to stimulate expansion within the viral inactivation market. These diseases, characterized by their ability to spread between individuals through contaminated food and drink, or via microorganisms like viruses, bacteria, fungi, and parasites, necessitate effective control measures. Viral inactivation plays a crucial role in public health initiatives by employing physical and chemical agents to neutralize viruses, thereby curbing the transmission of viral contagions and consequently fostering market growth. For example, as reported by the Centers for Disease Control and Prevention in March 2024, tuberculosis cases in the US saw a rise from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases, with the incidence rate climbing from 2.5 per 100,000 people in 2022 to 2.9 in 2023. This surge in various infectious disease occurrences directly contributes to the upward trajectory of the viral inactivation market.

    Viral Inactivation Market Segment Outlook: Which Categories Are Expanding The Fastest?

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    Viral Inactivation Market Industry Trends: What Changes Are Reshaping Demand?

    Key players within the viral inactivation sector are concentrating on the integration of cutting-edge viral clearance technologies to bolster the safety of biological products, ensure adherence to regulations, and optimize operational workflows. These sophisticated methods, which neutralize viruses via chemical, physical, or filtration approaches, facilitate achievements such as validating log reduction, guaranteeing regulatory-compliant viral safety, and expediting crucial decisions throughout the biologics development lifecycle. Illustratively, in May of 2025, Northway Biotech, a contract development and manufacturing organization (CDMO) based in Lithuania, introduced its Full-Service Viral Clearance Studies (VCS). This cutting-edge viral clearance solution is engineered to accelerate safety validation for protein biologics and gene therapies, boasting multiple identical BSL-2 laboratories to support high-throughput operations, BSL-3 testing capacities, and a turnaround time of less than 10 weeks for complete, regulatory-compliant viral clearance results, substantially quicker than typical industry timelines. This enhanced service empowers biopharma clientele by improving development velocity, bolstering cost management, and advancing their preparedness for regulatory scrutiny.

    Viral Inactivation Market Key Companies And Competitive Benchmarking

    Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG

    Access The Complete Viral Inactivation Market Report:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Viral Inactivation Market Geographic Analysis: Where Is Demand Growing The Fastest?

    North Americawas the largest region in the viral inactivation market in 2025. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Viral Inactivation Market Influenced by Innovations in Viral Clearance Technologies Enhancing Safety

    Viral Inactivation Market Influenced by Innovations in Viral Clearance Technologies Enhancing Safety

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Anticipated Rise In Market Value Of The Viral Inactivation Market During The Forecast Period?

    The viral inactivation market size has seen rapid expansion in recent years. It is anticipated to expand from $5.47 billion in 2025 to $6.05 billion in 2026, registering a compound annual growth rate (CAGR) of 10.6%. The historical growth of this market can be attributed to factors like the increasing production of plasma-derived products, the expansion of monoclonal antibody manufacturing, a rising regulatory emphasis on viral safety, the growth of biopharmaceutical manufacturing capacity, and the wider adoption of solvent detergent methods.

    The viral inactivation market is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $9.17 billion, demonstrating a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing demand for biologics and biosimilars, growing investments in advanced bioprocessing facilities, an intensified focus on continuous manufacturing, the wider adoption of automated quality control systems, and the expanding pipelines for vaccine production. Key trends emerging over the forecast period encompass the greater uptake of automated viral inactivation systems, an escalating demand for validated virus safety processes, the increased application of continuous flow inactivation methods, the broadening scope of single-use bioprocessing solutions, and a heightened emphasis on process reproducibility and compliance.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    What Primary Drivers Are Shaping The Viral Inactivation Market?

    The viral inactivation market is projected to expand in the future due to the increasing prevalence of various infectious diseases. These conditions are characterized by their transmission from one person to another, often via contaminated food and beverages, and through pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation finds extensive application in human disease control initiatives, where physical and chemical disinfectants are utilized to neutralize viruses and prevent the spread of contagious viral infections, thereby fostering the growth of the viral inactivation market. As an illustration, figures from March 2024 released by the Centers for Disease Control and Prevention, a US-based national public health agency, revealed an increase in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. The corresponding rate also rose from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Thus, the escalating incidence of diverse infectious diseases is a key driver for the growth of the viral inactivation market.

    How Are Different Segments Classified In The Viral Inactivation Market Segment Analysis?

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    What Trends Are Affecting The Growth Of The Viral Inactivation Market?

    Leading enterprises within the viral inactivation market are increasingly focusing on integrating cutting-edge viral-clearance technologies to elevate biologic safety, meet regulatory standards, and boost operational efficiency. These technologies achieve viral inactivation through chemical, physical, or filtration-based approaches, thereby enabling capabilities such as validating log reduction, ensuring regulatory-compliant viral safety, and expediting decision processes in biologics creation. For example, in May 2025, Northway Biotech, a contract development and manufacturing organization (CDMO) based in Lithuania, introduced Full-Service Viral Clearance Studies (VCS). This sophisticated viral-clearance solution is designed to speed up safety validation for protein biologics and gene therapies, incorporating several identical BSL-2 laboratories for efficient high-throughput workflows, BSL-3 testing capabilities, and providing complete regulatory-compliant viral clearance results in less than 10 weeks, which is considerably quicker than typical industry timeframes. This service significantly improves the pace of development, manages costs, and enhances regulatory preparedness for biopharma customers.

    Who Are The Companies Driving Activity In The Viral Inactivation Market?

    Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG

    Get The Full Viral Inactivation Market Report:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Which Region Accounts For The Largest Portion Of The Viral Inactivation Market?

    North America was the largest region in the viral inactivation market in 2025. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Viral Inactivation Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Browse Through More Reports Similar to the Global Viral Inactivation Market 2026, By The Business Research Company

    Oral Expectorant Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

    Antivirals Market Report

    https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

    Viral And Non Viral Vector Manufacturing Market Report

    https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Viral Inactivation Market Expected to Record Steady Growth and Approach $9.17 Billion by 2030

    Viral Inactivation Market Expected to Record Steady Growth and Approach $9.17 Billion by 2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Size Increase Is Anticipated For The Viral Inactivation Market Over The 2026–2030 Period?

    The market size for viral inactivation has experienced rapid expansion in recent times. Projected figures indicate its expansion from $5.47 billion in 2025 to $6.05 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.6%. Historically, this growth has been driven by factors such as the increasing production of plasma-derived products, the expansion of monoclonal antibody manufacturing, a heightened regulatory focus on viral safety, the growth in biopharmaceutical manufacturing capacity, and the broader acceptance of solvent detergent methods.

    The viral inactivation market is projected to experience substantial growth in the coming years. It is expected to reach $9.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.9%. This anticipated expansion during the forecast period is driven by factors such as the increasing demand for biologics and biosimilars, rising investments in advanced bioprocessing facilities, a growing focus on continuous manufacturing, the increasing adoption of automated quality control systems, and the expansion of vaccine production pipelines. Key trends identified for this period include the increasing adoption of automated viral inactivation systems, a rising demand for validated virus safety processes, the growing use of continuous flow inactivation methods, the expansion of single-use bioprocessing solutions, and an enhanced focus on process reproducibility and compliance.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    What Underlying Factors Are Accelerating The Growth Of The Viral Inactivation Market?

    The increasing occurrence of various infectious diseases is projected to drive the expansion of the viral inactivation market in the foreseeable future. Infectious diseases are conditions spread between individuals through contaminated food and drinks, or by pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation plays a crucial role in human disease control programs, utilizing physical and chemical disinfectants to neutralize viruses and curb the proliferation of contagious viral infections, thereby fueling the growth of the viral inactivation market. A notable example is the rise in tuberculosis cases: as reported by the Centers for Disease Control and Prevention in March 2024, cases in the United States escalated from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Concurrently, the rate grew from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Consequently, the rising prevalence of diverse infectious diseases is a significant factor propelling the growth of the viral inactivation market.

    How Is The Viral Inactivation Market Segmented Across Key Categories?

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    Which Upcoming Trends Are Expected To Influence The Viral Inactivation Market?

    Leading companies operating within the viral inactivation market are focusing on integrating advanced viral-clearance technologies to enhance biologic safety, improve regulatory compliance, and boost process efficiency. These technologies, which inactivate viruses through chemical, physical, or filtration mechanisms, facilitate capabilities such as log-reduction validation, regulatory-compliant viral safety assurance, and more rapid decision-making in biologics development. For instance, in May 2025, Northway Biotech, a Lithuania-based contract development and manufacturing organization (CDMO), launched Full-Service Viral Clearance Studies (VCS). This advanced viral-clearance solution is designed to accelerate safety validation for protein biologics and gene therapies, featuring multiple identical BSL-2 laboratories for high-throughput workflows, BSL-3 testing capabilities, and providing full regulatory-compliant viral clearance results in under 10 weeks, a timeline significantly faster than industry norms. This offering improves development speed, enables better cost control, and enhances regulatory readiness for biopharma clients.

    Who Are The Dominant Players Shaping The Viral Inactivation Market Landscape?

    Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG

    Read the full viral inactivation market report here:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Which Region Is Projected To Dominate The Viral Inactivation Market During The Forecast Period?

    North America was the largest region in the viral inactivation market in 2025. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Viral Inactivation Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    Browse Through More Reports Similar to the Global Viral Inactivation Market 2026, By The Business Research Company

    Oral Expectorant Global Market Report

    https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

    Antivirals Global Market Report

    https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

    Viral And Non Viral Vector Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Viral Inactivation Market Future Outlook 2026: Key Drivers and Growth Potential

    Viral Inactivation Market Future Outlook 2026: Key Drivers and Growth Potential

    Uncover key drivers, emerging technologies, and competitive movements shaping the viral inactivation market from 2026–2035 with trusted insights from The Business Research Company

    What is the expected shift in the Viral Inactivation Market’s size between 2026 and 2030?

    The viral inactivation market has experienced swift expansion recently. It is projected to grow from $5.47 billion in 2025 to $6.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The historical growth of this market can be attributed to several factors, including the increased production of plasma-derived products, the expansion in monoclonal antibody manufacturing, a rising regulatory focus on viral safety, the growth of biopharmaceutical manufacturing capacity, and the wider adoption of solvent detergent methods.

    The viral inactivation market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $9.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This growth throughout the forecast period can be linked to the increasing demand for biologics and biosimilars, rising investments in advanced bioprocessing facilities, a growing focus on continuous manufacturing, the increasing adoption of automated quality control systems, and the expansion of vaccine production pipelines. Prominent trends for the forecast period include the increasing adoption of automated viral inactivation systems, a rising demand for validated virus safety processes, the growing use of continuous flow inactivation methods, the expansion of single-use bioprocessing solutions, and an enhanced focus on process reproducibility and compliance.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    Which Drivers Are Shaping Strategic Decisions In The Viral Inactivation Market?

    The increasing occurrence of various infectious diseases is projected to drive the expansion of the viral inactivation market in the future. These diseases are defined as ailments communicable between individuals, transmitted by contaminated food and drinks, or by disease-causing agents like viruses, bacteria, fungi, and parasites. Viral inactivation sees extensive application in human disease management initiatives, where it employs physical and chemical disinfectants to neutralize viruses, thereby curbing the spread of infectious viral illnesses and consequently stimulating the growth of the viral inactivation market. For example, data from March 2024, provided by the Centers for Disease Control and Prevention, a national public health agency in the United States, indicated a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. The corresponding rate also saw an ascent from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Consequently, the rising prevalence of diverse infectious diseases is serving as a key impetus for the expansion of the viral inactivation market.

    What Segment Categories Are Covered In The Viral Inactivation Market?

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    What Upcoming Trends Are Likely To Define The Future Path Of The Viral Inactivation Market?

    Companies active in the viral inactivation market are increasingly focusing on integrating advanced viral-clearance technologies to improve biologic safety, ensure regulatory compliance, and boost process efficiency. These technologies achieve viral inactivation through chemical, physical, or filtration-based mechanisms, providing capabilities such as log-reduction validation, ensuring regulatory-compliant viral safety, and enabling quicker decision-making in biologics development. For example, in May 2025, Northway Biotech, a Lithuania-based contract development and manufacturing organization (CDMO), introduced Full-Service Viral Clearance Studies (VCS). This sophisticated viral-clearance solution is designed to accelerate safety validation for protein biologics and gene therapies, featuring multiple identical BSL-2 laboratories for high-throughput workflows, BSL-3 testing capabilities, and delivering comprehensive regulatory-compliant viral clearance results in under 10 weeks, which is considerably faster than typical industry standards. This offering enhances development speed, assists with cost control, and improves regulatory readiness for biopharma clients.

    Which Major Industry Participants Are Leading The Viral Inactivation Market Growth?

    Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Which Region Is Projected To Lead The Viral Inactivation Market During The Forecast Period?

    North America was the largest region in the viral inactivation market in 2025. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Viral Inactivation Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    Browse Through More Reports Similar to the Global Viral Inactivation Market 2026, By The Business Research Company

    Viral And Non Viral Vector Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

    Oral Expectorant Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

    Antivirals Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Viral Inactivation Market Revenue and CAGR Forecast Analysis 2025–2029

    Global Viral Inactivation Market Revenue and CAGR Forecast Analysis 2025–2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Future Growth Projections For The Viral Inactivation Market Size?

    The market size for viral inactivation has seen substantial expansion in the last few years. The market is expected to grow from $5.01 billion in 2024 to $5.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.2%. The surge in growth during the historic period can be credited to worldwide growth in air traffic, upgraded navigation capabilities, increased commercial aviation, savings in airline costs, enhanced flight safety, and decreased burden on pilots.

    The market size of viral inactivation is projected to experience swift expansion in the upcoming years. The market is forecasted to reach $8.24 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.8%. The predicted growth in this timeframe is largely due to the progression of autonomous flights, innovative aircraft designs, the push for eco-friendly aviation, urban air mobility (uam), and an escalating demand for aircraft. Trends that are anticipated to dominate this forecasted period include the adoption of cutting-edge avionics, the application of artificial intelligence, advancements in the human-machine interface (hmi), renovation of existing aircraft, and the incorporation of the global navigation satellite system (gnss).

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    Which Demand Drivers Are Strengthening The Viral Inactivation Market?

    The viral inactivation market is projected to expand due to the rising occurrences of various contagious ailments. Such illnesses, which include air and foodborne conditions caused by viruses, bacteria, fungi, and parasites, can be passed from one person to another. The use of viral inactivation techniques, involving physical and chemical disinfectants, is widespread in human disease control to mitigate the dissemination of viral contagions, thereby boosting the growth of the viral inactivation market. For exemplification, the Centers for Disease Control and Prevention, a US national public health institution, reported in March 2024 that tuberculosis cases surged from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. The frequency similarly ascended from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Consequently, the ascending prevalence of numerous infectious ailments is stimulating the expansion of the viral inactivation market.

    What Segmentation Insights Are Provided In The Viral Inactivation Market Research?

    The viral inactivationmarket covered in this report is segmented –

    1) By Product: Kits And Reagents; Systems; Services

    2) By Method: Solvent Detergent Method; pH Adjustment Method; Pasteurization; Other Methods

    3) By Application: Vaccines And Therapeutics; Tissues And Tissue Products; Blood And Blood Products; Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Blood Banks; Hospital; Academic Research Institutes; Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits; PCR Reagents; Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems; Batch Viral Inactivation Systems; Continuous Flow Systems

    3) By Services: Viral Testing Services; Validation Services; Consulting Services

    Which Trends Are Likely To Redefine Growth Paths In The Viral Inactivation Market?

    A primary trend emerging in the viral inactivation market is the escalating adoption of sophisticated technological processes. To maintain their market standing, entities active in this domain are embracing avant-garde technological methods. A prime illustration of this trend occurred in March 2022, when WuXi Advanced Therapies, an entirely owned subsidiary of WuXi AppTec, a biopharmaceutical company based in China, debuted their Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This ground-breaking technology has facilitated the sanctioning of new therapies by performing assay formulation, biosafety, viral clearance, product release, and testing concurrently and internally. This method presents an unprecedented innovative approach for producing adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade, eliminating the need for transfection.

    Which Firms Are Driving Innovation Within The Viral Inactivation Market?

    Major companies operating in the viral inactivation market include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Which Regional Markets Are Emerging As Key Hubs For The Viral Inactivation Market?

    North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    Browse Through More Reports Similar to the Global Viral Inactivation Market 2025, By The Business Research Company

    Viral Vectors And Plasmid Dna Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

    Antivirals Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

    Healthcare Personal Protective Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/healthcare-personal-protective-equipment-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Viral Inactivation Industry Forecast to Hit $8.24 Billion by 2029 With a Strong 10.8% CAGR

    Viral Inactivation Industry Forecast to Hit $8.24 Billion by 2029 With a Strong 10.8% CAGR

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Are The Current (2025) And Forecast (2029) Sizes Of The Viral Inactivation Market?

    The viral inactivation market size has seen substantial growth in recent years. Projections indicate it will increase from $5.01 billion in 2024 to $5.47 billion in 2025, at a compound annual growth rate (CAGR) of 9.2%. The historical growth can be attributed to several factors including global air traffic growth, enhanced navigation capabilities, commercial aviation expansion, airline cost savings, improved flight safety, and a reduction in pilot workload.

    The viral inactivation market is poised for significant expansion over the coming years, with projections indicating it will reach $8.24 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.8%. This anticipated growth is largely driven by factors such as the development of autonomous flight, advancements in next-generation aircraft designs, ongoing efforts toward sustainable aviation, the emergence of urban air mobility (UAM), and an increasing overall demand for aircraft. During this forecast period, major trends are expected to include the integration of advanced avionics, the widespread implementation of artificial intelligence, innovations in human-machine interfaces (HMI), the retrofitting of existing aircraft, and the enhanced integration of global navigation satellite systems (GNSS).

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Viral Inactivation Market?

    The viral inactivation market is expected to grow in the future due to the increasing prevalence of various infectious diseases. Infectious diseases are conditions that can be transmitted from one person to another through contaminated food and beverages, or via pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation is widely employed in human disease control programs to neutralize viruses using physical and chemical disinfectants, thereby preventing the spread of contagious viral infections and driving the growth of the viral inactivation market. For instance, in March 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported an increase in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. The associated rate also increased from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Therefore, the expanding instances of diverse infectious diseases are propelling the expansion of the viral inactivation market.

    What Are The Major Segment Types Covered In The Viral Inactivation Market?

    The viral inactivationmarket covered in this report is segmented –

    1) By Product: Kits And Reagents; Systems; Services

    2) By Method: Solvent Detergent Method; pH Adjustment Method; Pasteurization; Other Methods

    3) By Application: Vaccines And Therapeutics; Tissues And Tissue Products; Blood And Blood Products; Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Blood Banks; Hospital; Academic Research Institutes; Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits; PCR Reagents; Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems; Batch Viral Inactivation Systems; Continuous Flow Systems

    3) By Services: Viral Testing Services; Validation Services; Consulting Services

    Which Market Trends Are Creating New Opportunities In The Viral Inactivation Industry?

    The viral inactivation market is witnessing a significant trend toward the increased utilization of technologically advanced processes. Companies operating in this sector are embracing sophisticated processes to maintain their market standing. For instance, in March 2022, WuXi Advanced Therapies, a wholly-owned subsidiary of the China-based biopharmaceutical company WuXi AppTec, launched its Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This advanced technology has enabled the approval of new therapies by simultaneously conducting all assay formulation, biosafety, viral clearance, product release, and testing internally. This method offers an innovative approach for producing adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade without the need for transfection.

    Which Key Market Players Are Investing In Expansion And Innovation Of Viral Inactivation Market?

    Major companies operating in the viral inactivation market include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    How Is Viral Inactivation Market Demand Varying Across Different Regions?

    North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Request A Customized Version Of The Viral Inactivation Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    Browse Through More Reports Similar to the Global Viral Inactivation Market 2025, By The Business Research Company

    Viral Vectors And Plasmid Dna Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

    Antivirals Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

    Healthcare Personal Protective Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/healthcare-personal-protective-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Viral Inactivation Market to Reach $8.28 Billion by 2029 | Key Drivers and Future Outlook

    Viral Inactivation Market to Reach $8.28 Billion by 2029 | Key Drivers and Future Outlook

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Viral Inactivation Market?

    The size of the viral inactivation market has shown robust growth in the past few years. It is projected to increase from $5.01 billion in 2024 to $5.48 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.4%. The historical period’s growth can be associated with factors such as global air traffic surge, advanced navigation systems, commercial aviation development, airline cost efficiency, boosted flight safety, and decreased pilot workload.

    What Growth Rate Is Forecasted for the Viral Inactivation Market by 2029?

    The market size for viral inactivation is projected to experience a swift expansion in the coming years. The estimations point towards a growth that will reach “$8.28 billion by 2029”, marking a Compound Annual Growth Rate (CAGR) of 10.9%. The increase in the anticipated period owes its credit to advancements in autonomous flight technology, designing of future-generation aircrafts, commitment towards greener aviation, progress in urban air mobility (uam), and growing requirements for aircrafts. The period of forecast displays prominent trends such as incorporation of advanced avionics, application of artificial intelligence, human-machine interface (hmi) advancements, modification of existing aircrafts, and integration of global navigation satellite system (gnss).

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    Which Key Companies Are Shaping the Future of the Viral Inactivation Market?

    Major companies operating in the viral inactivation market include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

    Which Factors Are Driving Demand in the Viral Inactivation Industry?

    The surge in the occurrence of numerous infectious illnesses is anticipated to boost the viral inactivation market’s expansion. These diseases, transmissible via contaminated food and drink, or pathogens like viruses, bacteria, fungi, and parasites, refer to conditions that spread from one person to another. Viral inactivation, the utilization of physical and chemical disinfectants to deactivate viruses, is extensively used in human disease management, therefore contributing considerably to the market’s development. For instance, in March 2024, the US’s national public health agency, the Centers for Disease Control and Prevention, reported that tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, signifying an increase of 1,295 cases. The rate also grew from 2.5 per 100,000 people in 2022 to 2.9 in 2023. Consequently, the increasing infectious disease incidences are fuelling the expansion of the viral inactivation market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    How Is the Viral Inactivation Market Segmented by Several Divisions?

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    What are the Emerging Market Trends Driving the Growth of the Viral Inactivation Industry?

    There is a rising trend of companies in the viral inactivation market incorporating high-end technological processes, bolstering their market standing. An example of this was seen in March 2022, when WuXi Advanced Therapies, a fully-owned subsidiary of WuXi AppTec, a biopharmaceutical company from China, unveiled the Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This state-of-the-art technology accelerates the approval of new treatments by carrying out simultaneous assay formulation, biosafety checks, viral clearing, product launch, and testing internally. This highly innovative approach provides a new way to produce adeno-associated virus (AAV) of Good Manufacturing Practices (GMP) grade without necessitating transfection.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    Which Regions Are Driving Growth in the Viral Inactivation Market?

    North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10401

    This Report Delivers Insight On:

    1. How big is the viral inactivation market, and how is it changing globally?

    2. Who are the major companies in the viral inactivation market, and how are they performing?

    3. What are the key opportunities and risks in the viral inactivation market right now?

    4. Which products or customer segments are growing the most in the viral inactivation market?

    5. What factors are helping or slowing down the growth of the viral inactivation market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • How the Viral Inactivation Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)

    How the Viral Inactivation Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What Factors Are Propelling the Market Growth of theViral Inactivation Market from 2025 to 2034?

    The viral inactivation market is predicted to expand due to increasing incidences of numerous infectious diseases. These diseases, which can be transferred from one person to another through contaminated food and drinks and via pathogens such as viruses, bacterias, fungi, and parasites, call for the usage of viral inactivation. This technique is prevalently used in human disease-control programs where physical and chemical disinfectants are employed to deactivate viruses, aiding in preventing the transmission of virulent viral infections. As a result, this boosts the growth of the inactivation market. For instance, the Centers for Disease Control and Prevention, an American public health agency, indicated in March 2024 that the tuberculosis case count had surged from 8,320 in 2022 to 9,615 in 2023, translating to an increase of 1,295 cases. Moreover, the incidence rate also rose from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. For these reasons, the increasing occurrence of various infectious diseases is fuelling the growth of the viral inactivation market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

    #How Will the CAGR of the Viral Inactivation Market Influence Its Overall Growth by 2034?

    In recent periods, there has been sturdy growth in the size of the viral inactivation market. The market, which is projected to escalate from $5.01 billion in 2024 to $5.48 billion in 2025, is set to experience a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the historic period include the increase in global air traffic, advanced navigation capacities, expansion of commercial aviation, cost efficiencies achieved by airlines, enhanced flight safety, and decrease in pilot workload.

    The market size of viral inactivation is projected to experience a swift expansion in the following years, with estimates reaching up to “$8.28 billion in 2029 and showing a compound annual growth rate (CAGR) of 10.9%. Several factors expected to stimulate this growth in the projected period include advancements in autonomous flight, innovatory aircraft designs, initiatives towards sustainable aviation, urban air mobility (uam), and a growing demand for aircraft. The integration of advanced avionics, incorporation of artificial intelligence, innovations in the human-machine interface (hmi), retrofitting of existing aircraft, and integration of the global navigation satellite system (gnss) stand out as key trends in the forecast period.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10401

    How Are Market Trends and Innovations Revolutionizing theViral Inactivation Industry in Recent Times?

    The viral inactivation market is witnessing the growth of a key trend – the adoption of technologically advanced procedures. To remain competitive, corporations involved in the viral inactivation market are integrating these innovative methods. For instance, in March 2022, WuXi AppTec’s wholly-owned subsidiary, WuXi Advanced Therapies, launched a Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology from China. This state-of-the-art technology aids in the endorsement of new treatments through simultaneous, in-house assay formulation, biosafety, viral clearance, product release, and testing. This method offers a unique and innovative way to manufacture adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade without requiring transfection.

    Which Key Market Players Are Shaping the Future and Growth of theViral Inactivation Market?

    Major companies operating in the viral inactivation market include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

    #thebusinessresearchcompany #marketresearch #marketintelligence

    The viral inactivation market covered in this report is segmented –

    1) By Product: Kits And Reagents, Systems, Services

    2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods

    3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications

    4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

    Subsegments:

    1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes

    2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems

    3) By Services: Viral Testing Services, Validation Services, Consulting Services

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp

    What Regions Are Dominating the Viral Inactivation Market Growth?

    North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Reports Similar to the Gobal Viral Inactivation Maret 2025, By The Business Research Company:

    Healthcare E-Commerce Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/healthcare-ecommerce-global-market-report

    Healthcare Personal Protective Equipment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/healthcare-personal-protective-equipment-global-market-report

    Pharmacies and Healthcare Stores Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pharmacies-and-healthcare-stores-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: